Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
作者： C K Lee , H Gurney , C Brown , R Sorio , N Donadello
DOI: 10.1038/BJC.2011.256
关键词: Progression-free survival 、 Oncology 、 Carboplatin 、 Granulocyte colony-stimulating factor 、 Immunology 、 Internal medicine 、 Cancer 、 Paclitaxel 、 Medicine 、 Ovarian cancer 、 Leukopenia 、 Doxorubicin
摘要: Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer
nature.com
elsevier.com
core.ac.uk
sci-hub.se 参考文章(34)
E K Rowinsky, R C Donehower, V Chaudhry, D R Cornblath, Neurotoxicity of Taxol. Journal of The National Cancer Institute Monographs. ,vol. 1993, pp. 107- 115 ,(1993)
Peter Söderkvist, Henrik Green, Curt Peterson, G. Horvath, Per Rosenberg, In response [2] Clinical Cancer Research. ,vol. 12, ,(2006) , 10.1158/1078-0432.CCR-06-0461
B Uziely, S Jeffers, R Isacson, K Kutsch, D Wei-Tsao, Z Yehoshua, E Libson, F M Muggia, A Gabizon, Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. Journal of Clinical Oncology. ,vol. 13, pp. 1777- 1785 ,(1995) , 10.1200/JCO.1995.13.7.1777
H Gurney, Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. Journal of Clinical Oncology. ,vol. 14, pp. 2590- 2611 ,(1996) , 10.1200/JCO.1996.14.9.2590
Alan N. Gordon, John T. Fleagle, David Guthrie, David E. Parkin, Martin E. Gore, Angel J. Lacave, Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan Journal of Clinical Oncology. ,vol. 19, pp. 3312- 3322 ,(2001) , 10.1200/JCO.2001.19.14.3312
P Poikonen, T Saarto, J Lundin, H Joensuu, C Blomqvist, Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF British Journal of Cancer. ,vol. 80, pp. 1763- 1766 ,(1999) , 10.1038/SJ.BJC.6690594
Kohei Shitara, Keitaro Matsuo, Isao Oze, Ayako Mizota, Chihiro Kondo, Motoo Nomura, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy Cancer Chemotherapy and Pharmacology. ,vol. 68, pp. 301- 307 ,(2011) , 10.1007/S00280-010-1487-6
Howard Gurney, I don't underdose my patients…do I? Lancet Oncology. ,vol. 6, pp. 637- 638 ,(2005) , 10.1016/S1470-2045(05)70296-5
T Yamanaka, S Matsumoto, S Teramukai, R Ishiwata, Y Nagai, M Fukushima, Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. British Journal of Cancer. ,vol. 97, pp. 37- 42 ,(2007) , 10.1038/SJ.BJC.6603831
T Saarto, C Blomqvist, P Rissanen, A Auvinen, I Elomaa, Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. British Journal of Cancer. ,vol. 75, pp. 301- 305 ,(1997) , 10.1038/BJC.1997.49